-
Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC
04 Jul 2025 18:23 GMT
… received systemic treatment for metastatic … Notably, the trial protocol was … Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, Roche Diagnostics … fda.gov/drugs/;resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab …
-
m6A Modification of MEF2A Reduces Cetuximab Response
02 Jul 2025 01:57 GMT
… undermines the effectiveness of cetuximab treatment. This discovery, … traditionally associated with drug resistance. Consequently, … already entering clinical trials in other contexts, … cetuximab resistance offers hope for enhanced precision medicine. …
-
EGFR Inhibitors in the Treatment of Stage IV CRC
01 Jul 2025 22:21 GMT
… antibodies, basically panitumumab or cetuximab, with some of these … of work over many trials, including trials such as CALGB… studies using rechallenge with drugs like panitumumab in that … newer versions of these drugs, these bispecific antibodies that …
-
Non-Melanoma Skin Cancer: Deep Dive into Treatment Strategies for Cutaneous Squamous Cell Carcinoma
27 Jun 2025 03:38 GMT
… and High-Risk Treatment
Faculty agreed that outside clinical trials, adjuvant management … trial designs to avoid harming lower-risk patients.
cSCC: Neoadjuvant Treatment … (Alliance A091802) randomized trial of avelumab plus cetuximab versus avelumab alone in …
-
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
24 Jun 2025 20:13 GMT
… VS-7375 in combination with cetuximab in advanced solid tumors. … lack of FDA-approved, KRAS G12D-targeted treatments available to … developing and commercializing new medicines to improve the lives … of commencing and completing trials and compiling data, the …
-
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
23 Jun 2025 11:00 GMT
… 2025 website. About Purple Biotech
Purple Biotech Ltd. (NASDAQ… 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical products …
-
ISGIO Conference Highlights Emerging Trial Results Shaping GI Cancer Care
22 Jun 2025 17:49 GMT
… trials, novel drug approvals, and innovative therapeutic combinations are reshaping treatment … Medical Oncology Gastrointestinal Cancers Congress, presenting a deluge of trial … :
1. FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 …
-
NANOBIOTIX annonce une harmonisation réglementaire et le dépôt d’une demande d’un nouveau brevet de composition de matière pour JNJ-1900 (NBTXR3)
07 Jul 2025 20:15 GMT
… en tant que médicament permet une harmonisation réglementaire … Société »), société française de biotechnologie en phase de développement clinique … sous licence de Janssen Pharmaceutica NV, une société du … , avec ou sans cetuximab, pour le traitement …
-
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
07 Jul 2025 20:15 GMT
… biotechnology company pioneering physics-based approaches to expand treatment … which is licensed by Janssen Pharmaceutica NV, a Johnson … ) from a medical device to a drug, completing a process … with or without cetuximab, for the treatment of patients with …
-
OPC 2025: Early and Metastatic GI Cancers See Practice Changing Trial Results
20 Jun 2025 04:51 GMT
… summarizing recent clinical trial data shaping the treatment landscape for …
Despite the lack of FDA approval or formal inclusion … encorafenib (Braftovi; Pfizer), and cetuximab (Erbitux; Eli Lilly). A … nice to see negative trials published, because then we …